These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 30282634)

  • 21. Does Cardiovascular Comorbidity Influence the Prescribing of Bronchodilators in Chronic Obstructive Pulmonary Disease?
    Adesanoye DT; Willey CJ
    Ann Pharmacother; 2017 Oct; 51(10):855-861. PubMed ID: 28573879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of beta-blockers in patients with COPD: current perspective.
    Malerba M; Montuschi P; Radaeli A; Pirisi M
    Drug Discov Today; 2015 Jan; 20(1):129-35. PubMed ID: 25238736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.
    Dransfield MT; McAllister DA; Anderson JA; Brook RD; Calverley PMA; Celli BR; Crim C; Gallot N; Martinez FJ; Scanlon PD; Yates J; Vestbo J; Newby DE;
    Ann Am Thorac Soc; 2018 May; 15(5):608-614. PubMed ID: 29406772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease.
    Campo G; Pavasini R; Biscaglia S; Contoli M; Ceconi C
    Eur Heart J Cardiovasc Pharmacother; 2015 Jul; 1(3):205-11. PubMed ID: 27533997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations.
    Farland MZ; Peters CJ; Williams JD; Bielak KM; Heidel RE; Ray SM
    Ann Pharmacother; 2013 May; 47(5):651-6. PubMed ID: 23585645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.
    Brook RD; Anderson JA; Calverley PM; Celli BR; Crim C; Denvir MA; Magder S; Martinez FJ; Rajagopalan S; Vestbo J; Yates J; Newby DE;
    Heart; 2017 Oct; 103(19):1536-1542. PubMed ID: 28416587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
    Ding B; Small M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
    Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.
    Wang MT; Liou JT; Lin CW; Tsai CL; Wang YH; Hsu YJ; Lai JH
    JAMA Intern Med; 2018 Feb; 178(2):229-238. PubMed ID: 29297057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
    Gross N; Greos LS; Meltzer EO; Spangenthal S; Fishman RS; Spyker DA; Cassella JV
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):478-87. PubMed ID: 24745666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease.
    Lin SH; Perng DW; Chen CP; Chai WH; Yeh CS; Kor CT; Cheng SL; Chen JJ; Lin CH
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3051-3058. PubMed ID: 27980402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exacerbations of COPD.
    Pavord ID; Jones PW; Burgel PR; Rabe KF
    Int J Chron Obstruct Pulmon Dis; 2016; 11 Spec Iss(Spec Iss):21-30. PubMed ID: 26937187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).
    Duffy S; Marron R; Voelker H; Albert R; Connett J; Bailey W; Casaburi R; Cooper JA; Curtis JL; Dransfield M; Han MK; Make B; Marchetti N; Martinez F; Lazarus S; Niewoehner D; Scanlon PD; Sciurba F; Scharf S; Reed RM; Washko G; Woodruff P; McEvoy C; Aaron S; Sin D; Criner GJ;
    Respir Res; 2017 Jun; 18(1):124. PubMed ID: 28629419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.
    Rogliani P; Matera MG; Ora J; Cazzola M; Calzetta L
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3469-3485. PubMed ID: 29255354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of comorbidities in COPD patients by disease severity in a German population.
    Greulich T; Weist BJD; Koczulla AR; Janciauskiene S; Klemmer A; Lux W; Alter P; Vogelmeier CF
    Respir Med; 2017 Nov; 132():132-138. PubMed ID: 29229085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can beta-blockers be used for people with COPD?
    Drug Ther Bull; 2011 Jan; 49(1):2-5. PubMed ID: 21220252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study.
    Ivanov Y; Nikolaev I; Nemeth I
    Int J Chron Obstruct Pulmon Dis; 2018; 13():653-663. PubMed ID: 29503539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The airway pathophysiology of COPD: implications for treatment.
    Rodríguez-Roisin R
    COPD; 2005 Jun; 2(2):253-62. PubMed ID: 17136952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.